STOCK TITAN

Synaptogenix Inc - SNPX STOCK NEWS

Welcome to our dedicated news page for Synaptogenix (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on Synaptogenix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Synaptogenix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Synaptogenix's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-74.63%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
management clinical trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.97%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
Synaptogenix Inc

Nasdaq:SNPX

SNPX Rankings

SNPX Stock Data

5.09M
1.06M
2.44%
3.91%
1.1%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
New York

About SNPX

synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.